<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244035</url>
  </required_header>
  <id_info>
    <org_study_id>8266-008</org_study_id>
    <secondary_id>2010-021832-32</secondary_id>
    <nct_id>NCT01244035</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008 AM1)(COMPLETED)</brief_title>
  <official_title>Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Different Dosing Regimens of MK-8266 or Placebo in Subjects With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two part study comprising sequential double-dummy, placebo controlled 3-period
      randomized crossover studies. The study will evaluate the safety, tolerability,
      pharmacokinetics, and pharmacodynamics of different doses and dose regimens of MK-8266.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse experiences</measure>
    <time_frame>From day of enrollment to 10-14 days following the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the MK-8266 concentration versus time curve [AUC(0-τ)]</measure>
    <time_frame>Four days (Predose Day 1 of each study period through eight hours postdose on Day 4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration of MK-8266 (Cmax)</measure>
    <time_frame>Four days (Predose Day 1 of each study period through eight hours postdose on Day 4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration of MK-8266 (Tmax)</measure>
    <time_frame>Four days (Predose Day 1 of each study period through eight hours postdose on Day 4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life of MK-8266 (t½)</measure>
    <time_frame>Four days (Predose Day 1 of each study period through eight hours postdose on Day 4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average change from baseline in heart rate</measure>
    <time_frame>Baseline and average over 0-24 hours postdose on Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average change from baseline in diastolic blood pressure</measure>
    <time_frame>Baseline and average over 0-24 hours postdose on Day 3</time_frame>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part I - Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I - Sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I - Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I - Sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I - Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I - Sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II - Sequence DEF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II - Sequence DFE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II - Sequence EFD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II - Sequence EDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II - Sequence FDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II -Sequence FED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>MK-8266 orally twice daily (1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.</description>
    <arm_group_label>Part I - Sequence ABC</arm_group_label>
    <arm_group_label>Part I - Sequence ACB</arm_group_label>
    <arm_group_label>Part I - Sequence BCA</arm_group_label>
    <arm_group_label>Part I - Sequence BAC</arm_group_label>
    <arm_group_label>Part I - Sequence CAB</arm_group_label>
    <arm_group_label>Part I - Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>MK-8266 0.1 mg orally every 2 hours (total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.</description>
    <arm_group_label>Part I - Sequence ABC</arm_group_label>
    <arm_group_label>Part I - Sequence ACB</arm_group_label>
    <arm_group_label>Part I - Sequence BCA</arm_group_label>
    <arm_group_label>Part I - Sequence BAC</arm_group_label>
    <arm_group_label>Part I - Sequence CAB</arm_group_label>
    <arm_group_label>Part I - Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.</description>
    <arm_group_label>Part I - Sequence ABC</arm_group_label>
    <arm_group_label>Part I - Sequence ACB</arm_group_label>
    <arm_group_label>Part I - Sequence BCA</arm_group_label>
    <arm_group_label>Part I - Sequence BAC</arm_group_label>
    <arm_group_label>Part I - Sequence CAB</arm_group_label>
    <arm_group_label>Part I - Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D</intervention_name>
    <description>MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.</description>
    <arm_group_label>Part II - Sequence DEF</arm_group_label>
    <arm_group_label>Part II - Sequence DFE</arm_group_label>
    <arm_group_label>Part II - Sequence EFD</arm_group_label>
    <arm_group_label>Part II - Sequence EDF</arm_group_label>
    <arm_group_label>Part II - Sequence FDE</arm_group_label>
    <arm_group_label>Part II -Sequence FED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment E</intervention_name>
    <description>MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.</description>
    <arm_group_label>Part II - Sequence DEF</arm_group_label>
    <arm_group_label>Part II - Sequence DFE</arm_group_label>
    <arm_group_label>Part II - Sequence EFD</arm_group_label>
    <arm_group_label>Part II - Sequence EDF</arm_group_label>
    <arm_group_label>Part II - Sequence FDE</arm_group_label>
    <arm_group_label>Part II -Sequence FED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment F</intervention_name>
    <description>Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.</description>
    <arm_group_label>Part II - Sequence DEF</arm_group_label>
    <arm_group_label>Part II - Sequence DFE</arm_group_label>
    <arm_group_label>Part II - Sequence EFD</arm_group_label>
    <arm_group_label>Part II - Sequence EDF</arm_group_label>
    <arm_group_label>Part II - Sequence FDE</arm_group_label>
    <arm_group_label>Part II -Sequence FED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has essential hypertension who is in grade 1 or 2 hypertension according
             to the European Society of Hypertension (ESH) as delineated in the European Society of
             Cardiology (ESC) 2007 guidelines, i.e. systolic blood pressure values of 140-179 and
             diastolic blood pressure values of 90-109 on at least 3 occasions prior to the study.

          -  Otherwise healthy participants with grade 1 or 2 arterial hypertension who are treated
             with a single antihypertensive drug and meet the above blood pressure criteria may be
             enrolled at the discretion of the investigator

          -  Participant is generally in good health with the exception of hypertension

          -  Participant is a nonsmoker and/or has not used nicotine or nicotine-containing
             products for 6 months

        Exclusion Criteria:

          -  Participant has a history of any illness that might confound the results of the study
             or pose and additional risk to the participant if they take part in the study

          -  Participant has a history of stroke, chronic seizures, or major neurological disorder

          -  Participant has a disability that can interfere with rising from a semi-recumbent
             position to the standing position

          -  Participant has a personal or family history of a bleeding or clotting disorder

          -  Participant has a history of frequent nosebleeds or recurrent or active gingivitis

          -  Participant has a history of cancer, except 1) certain skin cancers; 2) cancer
             successfully treated more than 10 years prior to the study that has not recurred; or,
             3) participants who are unlikely to have a recurrence during the study

          -  Participant has a history of cardiac disease including but not limited to heart valve
             disease or evidence of secondary cardiac damage

          -  Participant is categorized as class II or greater according to the New York Heart
             Association (NYHA) functional classification for heart failure

          -  Participant is unable to refrain from use of prescription or non-prescription drugs or
             herbal remedies (such as St. John's Wort) during the study

          -  Participant anticipates using phosphodiesterase (PDE5) inhibitors [sildenafil
             (Viagra®), tadalafil (Cialis®), or vardenafil (Levitra®)] during the study

          -  Participant consumes excessive amounts of alcohol (more than 3 drinks per day) or
             caffeine (more than 6 servings a day)

          -  Participant has had major surgery, donated or lost 1 unit of blood, or participated in
             another investigational within 4 weeks prior to the study

          -  Participant has a history of multiple and/or severe allergies, or has had an
             anaphylactic reaction or intolerance to any drugs or food
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 20, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

